In short: Most patients with knee osteoarthritis should begin with a structured non-surgical plan — exercise, weight management, physical therapy and targeted medication. Regenerative options, including mesenchymal stem cell therapy, may be reasonable for selected patients with mild-to-moderate disease who have already tried conservative care. For advanced structural damage, knee replacement remains the more predictable route to pain relief.
Start with what the guidelines recommend
Knee replacement is a definitive option for advanced joint disease, but most patients should pursue a stepwise approach beginning with conservative care. National guidance emphasises education, exercise, weight management and targeted medical treatments before arthroplasty is considered (NICE, 2014; ACR/Arthritis Foundation, 2020).
Non-surgical essentials
- Education and self-management: disease education, activity modification and self-management programmes.
- Exercise and physical therapy: quadriceps strengthening, range-of-motion work and neuromuscular training.
- Weight loss: even modest reductions of 5–10% improve symptoms in patients who are overweight.
- Analgesics and topical agents: paracetamol and NSAIDs, oral or topical, chosen on safety profile.
- Bracing and orthotics: useful in unicompartmental disease or malalignment.
- Intra-articular injections: corticosteroids for flares; the evidence for hyaluronic acid is mixed.
If these measures fail to produce acceptable symptom relief and function, referral for surgical assessment is reasonable.
What regenerative medicine is, and what the evidence says
Regenerative approaches aim to reduce pain and improve joint function by modulating inflammation and supporting tissue repair. The two most common options are platelet-rich plasma (PRP) and mesenchymal stem/stromal cell (MSC) treatments.
Platelet-rich plasma (PRP)
PRP is an autologous blood-derived injection concentrated in platelets and growth factors that can reduce inflammation, modulate pain signalling and support local tissue healing. Clinical studies in mild-to-moderate knee osteoarthritis and some tendon injuries report pain relief and functional improvement lasting months, with a favourable safety profile because it uses the patient’s own blood. PRP is relatively low-cost, minimally invasive and repeatable. It is best suited to patients with early-to-moderate degenerative changes who have already failed first-line conservative care.
Mesenchymal stem cells (MSCs)
MSC therapies — in our case derived from umbilical cord Wharton’s jelly — have anti-inflammatory, immunomodulatory and trophic effects that may reduce pain and support tissue repair processes. Early clinical studies and case series report improvements in pain, function and sometimes imaging biomarkers in patients with mild-to-moderate joint degeneration. MSC treatments can be combined with rehabilitation protocols.
How the two differ
The distinction is mechanistic rather than a ranking. Stem cell treatments deliver living cells with broader biologic activity — paracrine signalling, immune modulation and secretion of growth factors — whereas PRP delivers a concentrated but finite pool of platelets and growth factors. Head-to-head clinical evidence establishing that one is superior to the other for knee osteoarthritis is still limited, and the right choice depends on the stage of disease, the patient’s goals and clinical judgement. Any clinic presenting one as definitively better than the other is ahead of the published data.
When regenerative therapy may be appropriate
Regenerative options may be worth discussing if the patient:
- Has persistent pain and functional limitation after an adequate trial of guideline-directed conservative care, typically over several months or years.
- Has stage 1, 2 or 3 osteoarthritis.
- Wishes to delay arthroplasty because of age, occupation or preference, and understands that outcomes vary between patients.
- Has realistic expectations, accepts the cost, and is medically suitable — no active infection, uncontrolled systemic disease, or contraindications to the procedure.
When surgery remains the correct indication
Knee replacement, partial or total, is typically indicated when:
- Severe pain substantially limits daily activities or sleep despite optimised non-surgical care.
- Radiographs show advanced joint destruction with deformity, instability or bone-on-bone disease.
In those situations, arthroplasty provides more predictable symptomatic and functional improvement, and we will say so.
How Stem Cells Colombia approaches this
- Comprehensive assessment: we confirm that conservative measures have been optimised, review imaging, and evaluate whether regenerative therapy suits the patient’s disease stage and goals.
- Standardised protocols: defined cell processing and delivery methods under strict sterility and safety protocols, with application guided by ultrasound in the operating room.
- Multimodal plan: stem cell treatment is offered as part of an integrated plan including rehabilitation and pain management.
- Informed consent and transparency: patients receive clear counselling on expected benefits, potential risks and likely costs.
You can read more about the cells we use and why, or see our knee and joint treatment in detail.
Patient selection and realistic expectations
Patients most likely to benefit are those with focal or mild-to-moderate cartilage loss, fewer comorbidities and realistic expectations. Some patients report meaningful pain relief and improved function lasting months to years; others have limited benefit. Results vary from person to person, and no regenerative treatment can be guaranteed to work.
Frequently asked questions
Do I have to have knee replacement surgery?
Not necessarily, and not immediately. Guidelines recommend a structured non-surgical programme first. Surgery becomes the reasonable next step when that programme fails and imaging shows advanced structural damage.
Can stem cell therapy regrow cartilage?
There is no reliable evidence that stem cell therapy regenerates cartilage to a normal state. The reported effects in clinical studies are mainly on pain and function, likely through anti-inflammatory and immunomodulatory mechanisms.
How long does the effect last?
Reported durations range from several months to a few years, and vary considerably between patients. Some patients experience little change. Outcome tracking at follow-up is the only honest way to know how you responded.
Am I too advanced for regenerative treatment?
If imaging shows bone-on-bone disease, deformity or instability, regenerative therapy is unlikely to give you what you want, and we will tell you that during the assessment rather than after the treatment.
Next step
If you are asking whether you have to have surgery, start with a structured non-surgical plan. For selected patients who meet clear criteria and want to explore regenerative options, we review your history, imaging and goals and recommend the safest, most evidence-aligned next step — including recommending surgery when that is the right answer.
References
- American College of Rheumatology & Arthritis Foundation. (2020). 2020 ACR/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. rheumatology.org
- National Institute for Health and Care Excellence. (2014). Osteoarthritis: care and management (CG177). nice.org.uk
- Cochrane Database of Systematic Reviews. (2015). Intra-articular corticosteroid and hyaluronic acid injections for knee osteoarthritis. cochranelibrary.com
- Cochrane Database of Systematic Reviews. (2018). Arthroscopic surgery for degenerative knee disease. cochranelibrary.com
This article is for general information and does not constitute medical advice. Stem cell therapy does not guarantee results and is not a cure. Eligibility requires review of your medical history and imaging by a physician. Individual results vary.